Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Novo NordiskNVO stock jumped Wednesday, breathing easily on a lighter-than-feared discount for its semaglutide-based products ...

The Trump administration’s negotiation with Novo Nordisk A/S that slashes 71% off the list price of its blockbusters Ozempic ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its ...

Discover why Novo Nordisk’s stagnating growth and lower obesity drug efficacy may signal more downside risk for investors.

The US government said Tuesday it negotiated a 71% discount off of the list price of Novo Nordisk A/S’s blockbuster drugs ...

Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk’s blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round ...

The lower prices stem from the Medicare negotiation program created under the Biden administration's Inflation Reduction Act.

How drugs were selected: Drugs were selected earlier this year based on criteria written into the law. They had to have no ...